BlueSphere Bio to Present at the Next Generation CAR & T Cell Therapies Conference PITTSBURGH, Pa., March 01, 2023 (GLOBE NEWSWIRE) -- BlueSphere Bio, a T-cell receptor (TCR) T-cell therapy company developing a powerful TCR discovery platform and novel therapeutic candidates for patients with hematologic malignancies and solid tumors, today announced Robert Keefe, Ph.D., Chief Development Officer of BlueSphere Bio, will present an overview of the Company’s anticipated first in human clinical candidate, BSB-1001, and its discovery using the TCXpress™ platform at the Next Generation CAR & T Cell Therapies Conference held in San Diego, CA from February 27 – March 3, 2023. Title: A Powerful Platform to Find TCRs to Defined Targets: Applications in Allogeneic Stem Cell Transplantation
Date: Thursday, March 2, 2023
Time: 11:30 a.m. – 12:00 p.m. PST
Location: San Diego Convention Center
For more information about the Next Generation CAR & T Cell Therapies Conference, please refer to the conference website at https://informaconnect.com/car-t/.
BlueSphere Bio is the first translational sciences stand-alone company formed by UPMC Enterprises, the innovation, commercialization, and venture capital arm of the Pittsburgh-based health system. The Company was founded upon the unique, advanced TCR discovery platform – TCXpress™, designed to isolate and functionally characterize TCRs with speed and efficiency. This platform can be used in various clinical settings to discover TCRs for use in either TCR-based cell therapy or in antibody-like molecules, such as bi-specific T cell engagers. While the Company’s initial focus is oncology, the platform could be deployed in other therapeutic areas, such as auto-immunity. In addition to TCX-101, BlueSphere is currently identifying a broad panel of TCRs to deploy in its first solid tumor program, which will be announced later this year. Concurrent with its use for shared antigens, BlueSphere is deploying TCXpress™ and NEOXpress™, a proprietary patient-specific neoantigen discovery platform, to develop its TCX-201 Program, which aims to identify TCRs reactive against patient-specific neoantigens. The Company anticipates virtual patient data from multiple solid tumor types this year. Senior Vice President, Head of Business Development & Strategy
amielach@lifescicomms.com